Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

May 21, 2024

BUY
$11.59 - $16.7 $5,725 - $8,249
494 Added 96.11%
1,008 $13,000
Q3 2023

Oct 30, 2023

BUY
$11.59 - $16.7 $5,725 - $8,249
494 Added 96.11%
1,008 $14,000
Q2 2023

May 21, 2024

BUY
$12.93 - $18.76 $801 - $1,163
62 Added 13.72%
514 $8,000
Q2 2023

Jul 27, 2023

BUY
$12.93 - $18.76 $801 - $1,163
62 Added 13.72%
514 $9,000
Q1 2023

May 21, 2024

BUY
$14.73 - $18.18 $1,664 - $2,054
113 Added 33.33%
452 $7,000
Q1 2023

Apr 27, 2023

BUY
$14.73 - $18.18 $1,664 - $2,054
113 Added 33.33%
452 $7,000
Q4 2022

May 21, 2024

BUY
$13.52 - $21.46 $4,583 - $7,274
339 New
339 $5,000
Q4 2022

Jan 31, 2023

BUY
$13.52 - $21.46 $4,583 - $7,274
339 New
339 $6,000

Others Institutions Holding HLVX

About HilleVax, Inc.


  • Ticker HLVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 33,427,200
  • Market Cap $58.8M
  • Description
  • HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.
More about HLVX
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.